Table 3.
Univariate cox regression analysis of progression-free survival and overall survival in trastuzumab-treated population.
| Progression-Free Survival | Overall Survival | |||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age | ||||
| <65 | 1.00 | 1.00 | ||
| ≥65 | 1.33 (0.78–2.28) |
0.291 | 1.62 (0.89–2.95) |
0.112 |
| Sex | ||||
| Male | 1.00 | 1.00 | ||
| Female | 1.12 (0.61–2.07) |
0.711 | 0.98 (0.50–1.95) |
0.964 |
| Histology | ||||
| Intestinal | 1.00 | 1.00 | ||
| Diffuse | 1.02 (0.52–2.00) |
1.18 (0.57–2.41) |
||
| Mixed | 1.79 (0.70–4.57) |
0.475 | 1.72 (0.60–4.90) |
0.576 |
| Clinical stage | ||||
| EGC | 1.00 | 1.00 | ||
| AGC | 1.62 (0.51–5.22) |
0.413 | 2.40 (0.58–9.94) |
0.226 |
| HER2 IHC | ||||
| <2+ | 1.00 | 1.00 | ||
| ≥2+ | 0.53 (0.13–2.21) |
0.383 | 0.79 (0.19–3.29) |
0.749 |
| HER2 IHC | ||||
| 1+, 2+ | 1.00 | 1.00 | ||
| 3+ | 0.23 (0.13–0.44) |
< 0.001 | 0.29 (0.15–0.55) |
<0.001 |
| Trastuzumab IHC | ||||
| <2+ | 1.00 | 1.00 | ||
| ≥2+ | 0.51 (0.30–0.88) |
0.016 | 0.47 (0.25–0.87) |
0.016 |
| Metastasis | ||||
| No | 1.00 | 1.00 | ||
| Yes | 1.79 (1.03–3.11) |
0.038 | 1.52 (0.83–2.79) |
0.180 |
Abbreviations: HR, hazard ratio; CI, confidence interval; p, p-value; EGC, early gastric cancer; AGC, advanced gastric cancer; IHC, immunohistochemistry.